Dihexa vs Cerebrolysin
These compounds occupy opposite ends of the neurotrophic spectrum. Dihexa is a single, well-characterised small molecule with an exceptionally strong preclinical synaptogenesis signal and no human data. Cerebrolysin is a complex biological preparation with decades of clinical use in approving jurisdictions and a correspondingly broad — but more mechanistically diffuse — evidence base.
Side-by-side
| Dihexa | Cerebrolysin | |
|---|---|---|
| Type | Single small peptide (hexapeptide) | Standardised multi-component preparation |
| Source | Synthetic (angiotensin IV-derived) | Enzymatic digest of porcine brain |
| Primary mechanism | HGF/c-Met agonism, synaptogenesis | Mimics multiple neurotrophic factors (BDNF, NGF, GDNF) |
| Route | Oral (in research) | Intravenous / intramuscular |
| Evidence | Strong preclinical; no human trials | Substantial clinical-trial body in stroke, dementia |
| Approved use | None | Approved in several jurisdictions (not UK/US/EMA-centralised) |
| UK status | Research chemical | Not licensed in the UK |
The fundamental difference
Dihexa: depth, not breadth
Cerebrolysin: breadth, not depth
Evidence-base architecture
Preclinical mechanism strength versus international clinical breadth
Dihexa's evidence-base architecture is a preclinical-depth positioning. The Washington State University research programme has characterised the compound extensively across in vitro cell-culture work, primary neuron cultures, ex vivo hippocampal slice preparations, and in vivo behavioural-endpoint testing in adult and aged animal cohorts. The picomolar-concentration spinogenesis finding, in particular, is among the most distinctive potency findings in the cognitive-plasticity peptide literature.
Cerebrolysin's evidence-base architecture is a clinical-breadth positioning. Multi-decade international RCT work covering vascular dementia, acute ischaemic stroke, Alzheimer's disease, and traumatic brain injury indications provides the broadest single-compound clinical evidence base in the Russian/CIS multi-component neuropeptide preparation family. Cochrane systematic-review coverage exists for the vascular dementia, acute stroke, and Alzheimer's disease indications.
Neither evidence-base fully substitutes for the other. Dihexa's preclinical-depth provides mechanism-level confidence but has zero human clinical-context data. Cerebrolysin's clinical-breadth provides substantial human clinical-context data but with pleiotropic multi-component mechanism-of-action framing that is inherently less mechanism-focused than single-molecule preclinical work.
Research-application selection
When to select Dihexa versus Cerebrolysin
Dihexa is the research-tool of choice for synaptic-plasticity mechanism research — research designs that need to isolate synaptogenesis effects at the dendritic spine level with mechanism-specific characterisation. The oral bioavailability is a further practical advantage for chronic-effect research designs.
Cerebrolysin is the research-tool of choice for translational research contexts where the clinical-application angle matters — post-stroke rehabilitation research, dementia research, and traumatic brain injury research where the compound's substantial international clinical-evidence base and licensed clinical use in approving jurisdictions provide translational-research context that Dihexa lacks. The parenteral administration route is a practical constraint but is standard for the clinical-application research context.
For research designs that need both mechanism-focused and clinical-application angles, the two compounds are complementary rather than substitutable — each provides research-tool positioning that the other cannot match.